Semin Thromb Hemost 2000; Volume 26(Number s1): 023-030
DOI: 10.1055/s-2000-9246
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Development of Tinzaparin: A Heparinase-Digested Low-Molecular-Weight Heparin

Ulla Hedner
  • University of Lund, Wallenberg Research Laboratories, University Hospital of Malmö, University of Lund, Sweden
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

Although heparin and its properties had been discovered in the early 1920s, the different characteristics associated with different molecular-weight fractions of heparin were only recognized in the late 1970s. Tinzaparin is a low-molecular-weight heparin (LMWH) produced by heparinase digestion of heparin. Preclinical research on tinzaparin established that there were no differences in the antithrombotic activity compared with heparin. Clinical studies evaluating tinzaparin vs. standard heparin for thromboprophylaxis of deep-vein thrombosis in general and orthopedic surgery found that tinzaparin was as effective as standard heparin. Tinzaparin was also evaluated vs. standard heparin in the treatment of acute proximal vein thrombosis; time-to-event curves suggested that this LMWH could be more effective than standard heparin.

KEYWORD

Tinzaparin - development - thromboprophylaxis - treatment of deep-vein thrombosis

REFERENCES

  • 1 Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis.  Acta Chir Scand Suppl . 1936;  79 407-413
    PubMedSearch in Google Scholar
  • 2 Crafoord C, Jorpes J. Heparin as a prophylaxis against thrombosis.  JAMA . 1941;  111 2831-2840
    PubMedSearch in Google Scholar
  • 3 Laurent T C. Studies on fractionated heparin.  Arch Biochem Biophys . 1961;  92 224-231
    CrossrefPubMedSearch in Google Scholar
  • 4 Johnson E A, Mulloy B. The molecular-weight range of mucosal-heparin preparations.  Carbohydr Res . 1976;  51 119-127
    CrossrefPubMedSearch in Google Scholar
  • 5 Denson K W, Bonnar J. The measurement of heparin. A method based on the potentiation of anti-factor Xa.  Thromb Diath Haemorrh . 1973;  30 471-479
    PubMedSearch in Google Scholar
  • 6 Yin E T, Wessler S, Butler J V. Plasma heparin: A unique, practical, submicrogram-sensitive assay.  J Lab Clin Med . 1973;  81 298-310
    PubMedSearch in Google Scholar
  • 7 Brinkhous K M, Smith H W, Warner E D, Seegers W H. The inhibition of blood clotting: An unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin to thrombin.  Am J Physiol . 1939;  125 683-687
    PubMedSearch in Google Scholar
  • 8 Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis.  Scand J Clin Lab Invest . 1968;  21 89-91
    PubMedSearch in Google Scholar
  • 9 Yin E T, Wessler S, Stoll P J. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor.  J Biol Chem . 1971;  246 3712-3719
    PubMedSearch in Google Scholar
  • 10 Yin E T, Wessler S, Stoll P J. Biological properties of the naturally occurring plasma inhibitor to activated factor X.  J Biol Chem . 1971;  246 3703-3711
    PubMedSearch in Google Scholar
  • 11 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem . 1973;  248 6490-6505
    PubMedSearch in Google Scholar
  • 12 Rosenberg R D. Actions and interactions of antithrombin and heparin.  N Engl J Med . 1975;  292 146-151
    CrossrefPubMedSearch in Google Scholar
  • 13 Friedel H A, Balfour J A. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.  Drugs . 1994;  48 638-660
    CrossrefPubMedSearch in Google Scholar
  • 14 Nielsen J I, Østergaard P. Chemistry of heparin and low molecular weight heparin.  Acta Chir Scand Suppl . 1988;  543 52-56
    PubMedSearch in Google Scholar
  • 15 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins.  Ann N Y Acad Sci . 1989;  556 333-353
    PubMedSearch in Google Scholar
  • 16 Bendetowicz A-V, Pacaud E, Beguin S, Uzan A, Hemker H C. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin enoxaparin.  Thromb Haemost . 1992;  67 556-562
    PubMedSearch in Google Scholar
  • 17 Mätzsch T, Bergqvist D, Bergqvist A. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin.  Blood Coagul Fibrinolysis . 1991;  2 273-278
    PubMedSearch in Google Scholar
  • 18 Pedersen P C, Østergaard P B, Hedner U, Bergqvist D, Mätzsch T. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers.  Thromb Res . 1991;  61 477-487
    CrossrefPubMedSearch in Google Scholar
  • 19 Mätzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.  Thromb Haemost . 1987;  57 97-101
    PubMedSearch in Google Scholar
  • 20 Fareed J, Walenga J M, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: Implications for clinical use and standardization.  Semin Thromb Hemost . 1989;  15 440-463
    PubMedSearch in Google Scholar
  • 21 Johnson E A. Comment on two papers by Dr. J. Fareed.  Haemostasis . 1989;  19 51-64
    PubMedSearch in Google Scholar
  • 22 Østergaard P B, Nilsson B, Bergqvist D, Hedner U, Pedersen P C. The effect of low molecular weight heparin on experimental thrombosis and haemostasis-The influence of production method.  Thromb Res . 1987;  45 739-749
    CrossrefPubMedSearch in Google Scholar
  • 23 Diness V, Nielsen J I, Pedersen P C, Wolffbrandt K H, Østergaard P B. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.  Thromb Haemost . 1986;  55 410-414
    PubMedSearch in Google Scholar
  • 24 Diness V, Østergaard P B. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.  Thromb Haemost . 1986;  56 318-322
    PubMedSearch in Google Scholar
  • 25 Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.  Thromb Haemost . 1990;  63 505-509
    PubMedSearch in Google Scholar
  • 26 Flessa H C, Kapstrom A B, Glueck H I, Will J J. Placental transport of heparin.  Am J Obstet Gynecol . 1965;  93 570-573
    CrossrefPubMedSearch in Google Scholar
  • 27 Omri A, Delaloye J F, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.  Thromb Haemost . 1989;  61 55-56
    PubMedSearch in Google Scholar
  • 28 Dawes J, Prowse C V, Pepper D S. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine.  Thromb Haemost . 1985;  54 630-634
    PubMedSearch in Google Scholar
  • 29 Liezorovicz A, Picolet H, Peyrieux J C, Boissel J P. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group.  Br J Surg . 1991;  78 412-416
    PubMedSearch in Google Scholar
  • 30 Hull R, Raskob G, Pineo G. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.  N Engl J Med . 1993;  329 1370-1376
    CrossrefPubMedSearch in Google Scholar
  • 31 Mätzsch T, Bergqvist D, Fredin H. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement.  Thromb Haemorrh Dis . 1991;  3 25-29
    PubMedSearch in Google Scholar
  • 32 Siegbahn A, Y-Hassan S, Boberg J. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.  Thromb Res . 1989;  55 767-778
    CrossrefPubMedSearch in Google Scholar
  • 33 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
    CrossrefPubMedSearch in Google Scholar
  • 34 Mätzsch T, Bergqvist D, Fredin H. Comparison of the thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement.  Thromb Haemorr Dis . 1991;  3 25-29
    PubMedSearch in Google Scholar
  • 35 Green D, Lee M Y, Lim A C. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.  Ann Intern Med . 1990;  113 571-574
    PubMedSearch in Google Scholar